公开(公告)号：US20180147286A1

公开(公告)日：2018-05-31

申请号：US15578226

申请日：2016-05-29

申请人： Jindrich Kopecek ,  Jiyan Yang ,  Purdue Research Foundation Office of Technology Commercialization ,  University of Utah Research Foundation

发明人： Stewart Andrew Low ,  Philip S. Low ,  Christopher Galliford ,  Jindrich Kopecek ,  Jiyan Yang

IPC分类号： A61K47/42 ,  A61M5/00 ,  A61P19/00 ,  A61K9/107 ,  A61K31/404

CPC分类号： A61K47/42 ,  A61K9/1075 ,  A61K31/404 ,  A61L27/22 ,  A61L27/227 ,  A61L27/54 ,  A61L2400/06 ,  A61L2430/02 ,  A61M5/002 ,  A61P19/00 ,  C07K7/06 ,  C07K7/08

摘要： Aspects of the present disclosure generally relate to compounds for targeting and healing bone fractures. Some of these compounds include a negatively charged oligopeptide comprising an acidic oligopeptide, a linker, which may be hydrolyzable or may be a substrate for the protease cathepsin K, and at least one molecule that promotes bone healing. In some compounds the molecule that promotes bone healing is an anabolic compound that inhibits GSK3β, in some compounds the molecule that promotes the healing of bone fracture is a pro-inflammatory agent such as PGE1. Other embodiments include methods of treating a bone fracture comprising administering a therapeutic amount of any one of the compounds disclosed herein.

公开(公告)号：US10279044B2

公开(公告)日：2019-05-07

申请号：US15578226

申请日：2016-05-29

申请人： Purdue Research Foundation Office of Technology Commercialization ,  University of Utah Research Foundation ,  Jindrich Kopecek ,  Jiyan Yang

发明人： Stewart Andrew Low ,  Philip S. Low ,  Christopher Galliford ,  Jindrich Kopecek ,  Jiyan Yang

IPC分类号： A61K31/404 ,  C07D403/04 ,  C07D209/34 ,  C07D487/00 ,  A61K47/42 ,  A61L27/22 ,  A61L27/54 ,  C07K7/06 ,  C07K7/08 ,  A61P19/00 ,  A61K9/107 ,  A61M5/00

摘要： Aspects of the present disclosure generally relate to compounds for targeting and healing bone fractures. Some of these compounds include a negatively charged oligopeptide comprising an acidic oligopeptide, a linker, which may be hydrolyzable or may be a substrate for the protease cathepsin K, and at least one molecule that promotes bone healing. In some compounds the molecule that promotes bone healing is an anabolic compound that inhibits GSK3β, in some compounds the molecule that promotes the healing of bone fracture is a pro-inflammatory agent such as PGE1. Other embodiments include methods of treating a bone fracture comprising administering a therapeutic amount of any one of the compounds disclosed herein.

公开(公告)号：US20190160172A1

公开(公告)日：2019-05-30

申请号：US16264364

申请日：2019-01-31

申请人： Purdue Research Foundation ,  University of Utah Research Foundation

发明人： Stewart Andrew Low ,  Philip S. Low ,  Christopher Galliford ,  Jindrich Kopecek ,  Jiyan Yang

IPC分类号： A61K47/42 ,  A61L27/22 ,  A61K9/107 ,  A61M5/00 ,  A61P19/00 ,  C07K7/08 ,  A61K31/404 ,  C07K7/06 ,  A61L27/54

CPC分类号： A61K47/42 ,  A61K9/1075 ,  A61K31/404 ,  A61L27/22 ,  A61L27/227 ,  A61L27/54 ,  A61L2400/06 ,  A61L2430/02 ,  A61M5/002 ,  A61P19/00 ,  C07K7/06 ,  C07K7/08

摘要： Aspects of the present disclosure generally relate to compounds for targeting and healing bone fractures. Some of these compounds include a negatively charged oligopeptide comprising an acidic oligopeptide, a linker, which may be hydrolyzable or may be a substrate for the protease cathepsin K, and at least one molecule that promotes bone healing. In some compounds the molecule that promotes bone healing is an anabolic compound that inhibits GSK3β, in some compounds the molecule that promotes the healing of bone fracture is a pro-inflammatory agent such as PGE1. Other embodiments include methods of treating a bone fracture comprising administering a therapeutic amount of any one of the compounds disclosed herein.

公开(公告)号：US10744203B2

公开(公告)日：2020-08-18

申请号：US16264364

申请日：2019-01-31

申请人： Purdue Research Foundation ,  University of Utah Research Foundation

发明人： Stewart Andrew Low ,  Philip S. Low ,  Christopher Galliford ,  Jindrich Kopecek ,  Jiyan Yang

IPC分类号： A61K31/404 ,  C07D403/04 ,  C07D209/34 ,  C07D487/00 ,  A61K47/42 ,  A61L27/22 ,  A61L27/54 ,  C07K7/06 ,  C07K7/08 ,  A61P19/00 ,  A61K9/107 ,  A61M5/00

摘要： Aspects of the present disclosure generally relate to compounds for targeting and healing bone fractures. Some of these compounds include a negatively charged oligopeptide comprising an acidic oligopeptide, a linker, which may be hydrolyzable or may be a substrate for the protease cathepsin K, and at least one molecule that promotes bone healing. In some compounds the molecule that promotes bone healing is an anabolic compound that inhibits GSK3β, in some compounds the molecule that promotes the healing of bone fracture is a pro-inflammatory agent such as PGE1. Other embodiments include methods of treating a bone fracture comprising administering a therapeutic amount of any one of the compounds disclosed herein.